biospecifics technologies corp.

Building a next-generation company on the foundation of our collagenase-based therapies

September 2020

Forward-Looking Statements

- This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding BioSpecifics Technologies Corp.’s (the “Company,” “our,” “we,” or “us”) strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management and the Board of Directors, expected revenue growth, shareholder value, the timing and occurrence of certain clinical trials, research and development plans, potential indications, indications in development, the timing and occurrence of commercial launches, future partnerships or acquisitions, and the assumptions underlying or relating to such statements, are “forward-looking statements.” In some cases, these statements can be identified by forward-looking words such as “expect,” “plan,” “anticipate,” “potential,” “estimate,” “can,” “will,” “continue,” “should,” “believe,” “schedule,” “intend,” the negative or plural of these words, and other similar expressions. These forward-looking statements are predictions based on our current expectations and our projections about future events and various assumptions. There can be no assurance that we will realize our expectations or that our beliefs will prove correct. These forward-looking statements involve known and unknown risks, uncertainties, and other factors, which may be beyond our control, and which may cause the actual results, performance, or achievements of the Company to be materially different from future results, performance, or achievements expressed or implied by such forward-looking statements. There are a number of factors that could cause the Company’s actual results to differ materially from those indicated by such forward-looking statements, including, without limitation: the timing of regulatory filings and action; the ability of Endo International plc (“Endo”) to achieve its objectives for XIAFLEX® and Qwo™; the market for XIAFLEX® in, and timing, initiation, and outcome of clinical trials for, additional indications, which will determine the amount of milestone, royalty, mark-up on cost of goods sold, and license and sublicense income that the Company may receive; the potential of XIAFLEX® to be used in additional indications; Endo’s modification of its objectives or reallocation of its resources with respect to XIAFLEX® and Qwo™; the impacts of the novel coronavirus (COVID-19) global pandemic; and the outcome of our pending arbitration with the Research Foundation of the State University of New York. All forward-looking statements included in this presentation are made as of the date hereof, and are expressly qualified in their entirety by this cautionary notice, including, without limitation, those risks and uncertainties described in our Annual Report on Form 10-K for the year ended December 31, 2019, our Form 10-Q for the fiscal quarter ended March 31, 2020, our Form 10-Q for the fiscal quarter ended June 30, 2020, and otherwise in our filings and reports filed with the Securities and Exchange Commission. Except as may be required by law, we assume no obligation to update these forward-looking statements.

Company Overview (NASDAQ: BSTC)

Continuing to maximize the XIAFLEX®/CCH portfolio

- XIAFLEX® commercial indications: Peyronie's disease and Dupuytren's contracture
- Qwo™ (collagenase clostridium histolyticum-aaes), first FDA-approved injectable treatment for cellulite
- XIAFLEX ® indications in development: adhesive capsulitis & plantar fibromatosis

Opportunistic about business development opportunities to diversify portfolio

- Strong cash position
- No debt
- Supported by royalty revenues from partner Endo for marketed XIAFLEX® indications
- Prudent cash management

biospecifics technologies corp.

XIAFLEX® is a registered trademark of Endo Pharmaceuticals

Strong Balance Sheet to Support Future Growth Initiatives

Lean corporate structure and strong balance sheet

~$119.8M

in cash as of 6/30/20

$13.6M

1H20 royalties received from Endo sales of XIAFLEX®

0

Debt

Seeking to partner with companies that possess novel therapeutics that will deliver meaningful benefits for patients

biospecifics technologies corp.

Commercial and Development Pipeline

Biopharmaceutical company that originated and continues to develop, in collaboration with Endo Pharmaceuticals, a first-in-class collagenase-based portfolio of commercial and clinical assets

Collagenases are naturally occurring enzymes responsible for the breakdown of collagen

Collagen is the main structural protein in the extracellular matrix in the various connective tissues of the body and is the most abundant protein in mammals

Local accumulations of excess collagen are associated with a number of medical conditions

biospecifics technologies corp.

Multiple Conditions Associated with Collagen Accumulation

Medical indications, marketed as XIAFLEX®	• Dupuytren's contracture • Peyronie's disease
Approved aesthetic indication, to be marketed as Qwo™	• Cellulite
XIAFLEX® medical indications in development	• Adhesive capsulitis (frozen shoulder) • Plantar fibromatosis
Potential future indications for XIAFLEX®	• Multiple new indications under evaluation

biospecifics technologies corp.

Diverse Pipeline



biospecifics technologies corp.

Source: Endo International plc

XIAFLEX® Commercial Indications

biospecifics technologies corp.

Peyronie’s Disease

Characterized by presence of a collagen plaque on the shaft of the penis

- Can distort an erection and make sexual intercourse difficult or even impossible in advanced cases
- In some mild cases, the plaque can resolve spontaneously without medical intervention
- In severe cases, the penis can be bent at a 90-degree angle during erection

XIAFLEX® is the first and only FDA-approved biologic therapy indicated for the treatment of Peyronie's disease in men with a palpable plaque and a curvature of 30 degrees or greater at the start of therapy.

XIAFLEX®
collagenase clostridium histolyticum

biospecifics technologies corp.

Source: Endo International plc

Dupuytren's Contracture

Deforming condition of the hand in which one or more fingers contract toward the palm

- Onset is characterized by the formation of nodules at the juncture between the fingers and palm that are composed primarily of collagen
- As the disease progresses, collagen nodules begin to form a cord causing the patient's finger(s) to contract, making it impossible to open the hand fully

XIAFLEX® is the first and only FDA-approved nonsurgical treatment for Dupuytren's contracture patients with a palpable cord

XIAFLEX®
collagenase clostridium histolyticum

biospecifics technologies corp.

Source: Endo International plc

Qwo™ Aesthetic Indication

biospecifics technologies corp.

Qwo™ for Cellulite

Skin dimpling occurring mainly on the buttocks, thighs and lower abdomen and arms

- Affects **~85-90%** of post-pubertal females
- First FDA-approved pharmaceutical product to address fibrous septae primarily composed of collagen

FDA Status

- Approved July 2020
- Commercial launch anticipated in first half 2021

Qwo™
collagenase clostridium histolyticum-aaes injection 0.92mg

biospecifics technologies corp.

Source: Endo International plc

XIAFLEX® Development Pipeline

biospecifics technologies corp.

Adhesive Capsulitis

Inflammation and thickening of shoulder capsule due to collagen, limiting the range of motion of the shoulder

- Common available treatment options are often painful and can require anesthesia
- Long-term intensive physical therapy, corticosteroids, manipulation under anesthesia and /or arthroscopic release
- Condition can last ~1 year to up to 3.5 years

Market Opportunity

- 3.5% prevalence with ~40% cases having primary idiopathic adhesive capsulitis
- ~200K surgeries performed annually
- Potential to be only FDA-approved nonsurgical therapy

First patient dosed in 2Q20

biospecifics technologies corp.

Source: Endo International plc

Plantar Fibromatosis

Pain and disability caused by the thickening of the feet's deep connective tissue

- Formation of nodules or cords along plantar fascia
- Patients often have Dupuytren's disease, Peyronie's disease and adhesive capsulitis

Market Opportunity

- ~3-3.5M patients with plantar fasciitis or plantar fibromatosis
  - Plantar fibromatosis affects **5-10%**
- Current treatments include orthotics and anti-inflammatory drugs in the early stages of the disease, steroid injections and surgery in advanced cases

First patient dosed in 2Q20

biospecifics technologies corp.

Source: Endo International plc

Additional Unlicensed Potential XIAFLEX Indications

Uterine fibroids	• Benign tumors in the reproductive tract with large amounts of collagen causing pain and complications
Hypertrophic Scars & Keloids	• Scars that form on the skin at site of injury
Knee Arthrofibrosis	• Adhesions that form post-implant that may affect range of motion
Urethral Strictures	• Narrowing of the urethra that may affect urine flow

biospecifics technologies corp.

BSTC Corporate Overview

biospecifics technologies corp.

Financial Highlights from 1H20

	For the six months ended	
	6/30/2020	6/30/2019
Cash and equivalents, and investments	**$119,843,584**	**$93,509,884**
Income Statement		
Revenues	$13,572,069	$16,982,127
Other income	870,597	966,580
Costs and expenses	(8,590,383)	(4,946,141)
Provision for income taxes	(1,237,681)	(2,159,511)
Net income	**$ 4,614,602**	**$10,843,055**
Earnings per share:		
Basic	**$ 0.63**	**$ 1.49**
Diluted	**$ 0.63**	**$ 1.48**
Shares used in computation of earnings per share:		
Basic	**7,337,564**	**7,292,663**
Diluted	**7,361,256**	**7,344,008**

7.3 million shares outstanding as of 6/30/20

biospecifics technologies corp.

Corporate Outlook and Upcoming Milestones

Continue to receive royalty revenues from partner Endo for marketed XIAFLEX® indications

- Royalty revenue decreased 56% year-over-year for 2Q20
- Endo expects full year 2020 revenues to be lower than 2019 due to COVID-19
- IP through 2028

Opportunistic about Business Development opportunities

- Expanding BioSpecifics beyond XIAFLEX®/CCH
- Partner with companies that possess novel therapeutics that will deliver meaningful benefits for patients

Continue to advance diverse development pipeline

- FDA approval for cellulite indication July 2020; launch expected in 1H21
- First patient dosed in both adhesive capsulitis and plantar fibromatosis trials in 2Q20
- Continued evaluation of multiple new potential indications

biospecifics technologies corp.

Building a next-generation company on the foundation of our collagenase-based therapies

September 2020